Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.14365/5558
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSiriratnam, Pakeeran-
dc.contributor.authorSanfilippo, Paul-
dc.contributor.authorvan der Walt, Anneke-
dc.contributor.authorSharmin, Sifat-
dc.contributor.authorFoong, Yi Chao-
dc.contributor.authorYeh, Wei Zhen-
dc.contributor.authorZhu, Chao-
dc.date.accessioned2024-10-25T15:17:49Z-
dc.date.available2024-10-25T15:17:49Z-
dc.date.issued2024-
dc.identifier.issn0022-3050-
dc.identifier.issn1468-330X-
dc.identifier.urihttps://doi.org/10.1136/jnnp-2024-334090-
dc.identifier.urihttps://hdl.handle.net/20.500.14365/5558-
dc.description.abstractBackground Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. Methods This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. Results A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p<0.001) and seronegative NMOSD (HR 0.21, 95% CI 0.08 to 0.51, p<0.001). Longer disease duration (HR 0.97, 95% CI 0.95 to 0.99, p<0.001) and male sex (HR 0.52, 95% CI 0.34 to 0.84, p=0.007) were additional protective variables in reducing the recurrent relapse risk for the AQP4-IgG NMOSD group. Conclusion Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.en_US
dc.language.isoenen_US
dc.publisherBmj Publishing Groupen_US
dc.relation.ispartofJournal of neurology neurosurgery and psychiatryen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMULTIPLE SCLEROSISen_US
dc.subjectNEUROIMMUNOLOGYen_US
dc.subjectIMMUNOLOGYen_US
dc.subjectMEDICINEen_US
dc.subjectHEALTH ECONOMICSen_US
dc.subjectOptica Spectrum Disorderen_US
dc.subjectNeuromyelitis-Opticaen_US
dc.subjectDouble-Blinden_US
dc.subjectEfficacyen_US
dc.subjectSafetyen_US
dc.subjectAzathioprineen_US
dc.subjectSatralizumaben_US
dc.subjectRituximaben_US
dc.subjectOutcomesen_US
dc.titlePredictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studyen_US
dc.typeArticleen_US
dc.typeArticle; Early Accessen_US
dc.identifier.doi10.1136/jnnp-2024-334090-
dc.identifier.pmid39231582en_US
dc.identifier.scopus2-s2.0-85204235831en_US
dc.departmentİzmir Ekonomi Üniversitesien_US
dc.authoridSiriratnam, Pakeeran/0000-0003-4751-2102-
dc.authoridFoschi, Matteo/0000-0002-0321-7155-
dc.authorwosidFoschi, Matteo/ABR-7231-2022-
dc.authorwosidSiriratnam, Pakeeran/AGX-6343-2022-
dc.authorwosidMonif, Mastura/L-4124-2019-
dc.authorwosidSoysal, Aysun/AAX-7696-2021-
dc.authorscopusid57210635745-
dc.authorscopusid6701687565-
dc.authorscopusid35079672200-
dc.authorscopusid55028512500-
dc.authorscopusid55258457800-
dc.authorscopusid57201885527-
dc.authorscopusid57348355200-
dc.identifier.wosWOS:001309611300001en_US
dc.institutionauthor-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
item.grantfulltextnone-
item.openairetypeArticle-
item.openairetypeArticle; Early Access-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.cerifentitytypePublications-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

Page view(s)

12
checked on Nov 18, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.